• Explore /
  • Poster
  • / Subtype-specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced LPS and leiomyosarcoma (LMS).

Subtype-specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced LPS and leiomyosarcoma (LMS).

Abstract Poster

Authors

null

Sant P. Chawla

Director, Sarcoma Oncology Center, Santa Monica, CA

Sant P. Chawla , Patrick Schöffski , Giovanni Grignani , Jean-Yves Blay , Robert G. Maki , David R. D'Adamo , Matthew Guo , George D. Demetri

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Soft Tissue Tumors

Clinical Trial Registration Number

NCT01327885

Citation

J Clin Oncol 34, 2016 (suppl; abstr 11037)

DOI

10.1200/JCO.2016.34.15_suppl.11037

Abstract #

11037

Poster Bd #

163

Abstract Disclosures

Similar Posters

First Author: Shibu Thomas

First Author: Mark Andrew Dickson

First Author: Shanu Modi

First Author: Scott Schuetze